Study on timing cancer treatments to the morning comes under fire

A recent clinical trial published in Nature Medicine has sparked controversy and skepticism within the scientific community. The study suggested that administering immunotherapy infusions in the morning, rather than the afternoon, could significantly reduce the risk of progression in lung cancer patients. However, concerns have been raised about the validity of the data and the overall study design.

Several scientists and researchers have pointed out inconsistencies in the trial, including discrepancies in the trial design on its clinicaltrials.gov registration page, chronological errors in the submitted trial protocol, and questionable progression-free survival data. Additionally, there are anomalies in the reported side effects or adverse events from the treatment. These issues have cast doubt on the study’s conclusions, which experts had already deemed to lack strong biological plausibility.

Nature Medicine has acknowledged the concerns raised by the scientific community and has initiated an investigation into the matter. The study authors have refrained from commenting on the criticisms and have stated that they are currently preparing a response to address the issues.

The controversy surrounding this study highlights the importance of rigorous scientific scrutiny and transparency in clinical research. As the investigation unfolds, it will be crucial to evaluate the integrity of the data and the validity of the study’s findings. Stay tuned for updates on this developing story.